Depok – South Korean pharmaceutical company Daewoong has announced a significant 34.1 billion won ($25 million) export contract with Colombian pharmaceutical company Valentech Pharma for its botulinum toxin product Nabota. This agreement represents a strategic entry into Latin America’s third-largest cosmetic surgery market and demonstrates Daewoong’s aggressive international expansion strategy.

Strategic Partnership with Experienced Colombian Distributor

Valentech Pharma brings substantial pharmaceutical expertise to the partnership, with an established track record in obtaining regulatory approvals for rare disease treatments and biosimilar products. The Colombian company has recently expanded its operations into the aesthetic medicine sector, making it an ideal partner for Daewoong’s market entry strategy.

The collaboration positions both companies to leverage their respective strengths—Daewoong’s proven botulinum toxin technology and Valentech’s regulatory expertise and local market knowledge in Colombia’s growing aesthetic medicine landscape.

Colombia Presents Substantial Market Opportunity

Colombia represents a particularly attractive market for aesthetic treatments, ranking as Latin America’s third-largest beauty and plastic surgery consumer market behind Brazil and Mexico. The country shows exceptional growth potential in non-invasive procedures, with botulinum toxin treatments leading this expansion.

Market research firm Grand View Research projects remarkable growth for Colombia’s non-invasive cosmetic procedure market, forecasting expansion from $940 million in 2023 to $2.613 billion by 2030. This represents an impressive average annual growth rate of 15.7%, indicating sustained demand for aesthetic treatments like botulinum toxin injections.

Competitive Positioning Against Market Leader

Daewoong’s Nabota has demonstrated competitive advantages through comparative clinical trials against AbbVie’s Botox, currently the dominant botulinum toxin product globally. The companies plan to leverage Nabota’s proven efficacy and effectiveness to capture significant market share in Colombia’s expanding aesthetic medicine sector.

The product has gained quality recognition from major international regulatory agencies, including approvals from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada. This regulatory validation provides credibility for market entry in Colombia and other Latin American countries.

Ambitious Market Share Goals and Timeline

Both Daewoong and Valentech Pharma have established aggressive growth targets for the Colombian market. Through localized marketing activities and strategic product positioning, the companies aim to achieve a 30% market share and secure second place in Colombia’s botulinum toxin market within five years of launch.

The timeline reflects confidence in Nabota’s competitive advantages and the partners’ ability to execute effective market penetration strategies in Colombia’s receptive aesthetic medicine environment.

Medical Tourism Dimension Adds Growth Potential

Colombia’s emergence as a medical tourism destination adds another layer of opportunity for Nabota’s market entry. The country’s reputation for high-quality aesthetic procedures at competitive prices attracts international patients, potentially expanding the customer base beyond domestic consumers.

Yoon Jun-soo, head of Daewoong’s Nabota Business Division, emphasized the significance of establishing a foundation for expanding Nabota in Colombia, a major beauty and plastic surgery consumer market in Latin America that has also recently gained attention as a medical tourism destination.

Platform for Regional Expansion

The Colombian contract serves as a strategic launching pad for broader Latin American market penetration. Success in Colombia’s competitive aesthetic medicine market could facilitate expansion into neighboring countries and establish Daewoong as a major player in the region’s growing non-invasive cosmetic procedure sector.

This partnership demonstrates how Korean pharmaceutical companies are successfully competing with established Western brands in international aesthetic medicine markets through superior product performance, competitive pricing, and strategic local partnerships.

Original Article:

Choi, M. (2025). Daewoong’s botulinum toxin secures 34.1 bil. won export contract with Colombia. Business Korea. Retrieved from https://www.businesskorea.co.kr/news/articleView.html?idxno=250290